Search company, investor...
Stentys company logo


Founded Year




Total Raised


About Stentys

Stentys is developing and commercializing solutions for the treatment of patients with acute myocardial infarction (AMI, or heart attack) and complex coronary artery disease. Stentys' Self-Apposing Stents are designed to adapt to vessels with ambiguous or fluctuating diameters, particularly in the post-infarction phase, in order to prevent the malapposition problems associated with conventional stents.

Headquarters Location

31 Rue Saint-Augustin

Paris, 75002,


+33 1 44 53 99 42

Missing: Stentys's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Stentys's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Stentys Patents

Stentys has filed 3 patents.

patents chart

Application Date

Grant Date


Related Topics




Implants (medicine), Cardiology, Cardiac arrhythmia, Vascular diseases, Heart diseases


Application Date


Grant Date



Related Topics

Implants (medicine), Cardiology, Cardiac arrhythmia, Vascular diseases, Heart diseases



Latest Stentys News

L'augmentation de capital de Stentys souscrite à 131 %

Sep 18, 2022

Partager - 14 conseils Deux ans après son IPO, le fabricant de prothèses vasculaires relève sur Euronext 36,4 M€, dont plus de 10 M€ auprès du fonds public.. Le fabricant coté de prothèses vasculaires réunit 36,4 M€, dont plus de 10 M€ auprès du FSI qui s'offre ainsi 8 % du capital, en vue de son déploiement commercial en Europe et son implantation aux Etats-Unis.smallNouveau succès de Stentys sur le marché. Deux ans après son IPO sur Euronext et dix mois après avoir obtenu un placement privé d'un montant de 8,3 M€ (lire ci-dessous), le fabricant de stents, des prothèses en forme de ressort placées dans les artères, utilisées notamment pour le traitement des infarctus du myocarde, lève 36,4 M€ supplémentaires à l'occasion d'une nouvelle augmentation de capital. Le FSI, qui s'était engagé à y participer pour un montant maximum de 15 M€ a finalement apporté un peu (...) Cet article est réservé à nos abonnés. 86% reste à lire Pour accéder à cet article, à l'ensemble du site ainsi qu'à nos bases de données, découvrez nos formules d'abonnement .

Stentys Frequently Asked Questions (FAQ)

  • When was Stentys founded?

    Stentys was founded in 2005.

  • Where is Stentys's headquarters?

    Stentys's headquarters is located at 31 Rue Saint-Augustin, Paris.

  • What is Stentys's latest funding round?

    Stentys's latest funding round is PIPE.

  • How much did Stentys raise?

    Stentys raised a total of $22.2M.

  • Who are the investors of Stentys?

    Investors of Stentys include Alpha Blue Ocean, Omnes Capital, Scottish Equity Partners and Sofinnova Partners.

  • Who are Stentys's competitors?

    Competitors of Stentys include Reva Medical, AlterG, Mercator MedSystems, ArraVasc, InfraReDx and 11 more.

Compare Stentys to Competitors

Fox Hollow Technologies

Fox Hollow Technologies, Inc. has developed a coronary catheter that facilitates complete coronary lesion de-bulking, which has been shown to significantly reduce restenosis. The company's technology is designed to address the needs of the interventional cardiologist for a process that has traditionally been complex and has not allowed for complete de-bulking.

InfraReDx Logo

InfraReDx is a medical device company dedicated to helping provide practitioners with the information needed for enhanced clinical decision making in treating coronary artery disease. The company is committed to improving the safety and efficacy of coronary stenting and ultimately serving as part of a strategy to prevent initial coronary events. Through its TVC Imaging System, InfraReDx is changing the way coronary artery disease is diagnosed and treated. The TVC Imaging System is the only intravascular imaging system that enables true vessel characterization through simultaneous structural and compositional imaging data obtained in a single pullback.

Endologix Logo

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.

Tryton Medical Logo
Tryton Medical

Tryton Medical is a developer of stent systems for the treatment of bifurcation lesions. The Tryton Side Branch Stent System is built for bifurcation using Tri-ZONE technology to offer a dedicated strategy for treating bifurcation lesions. Tryton's cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel. The stent system has received CE Mark and is commercially available throughout Europe, Russia and the Middle East. It is approved in the United States for investigational use only.

Reva Medical

REVA Medical develops interventional medical devices that leverage the company's stent designs and biomaterials to improve the treatment of vascular disease. Its flagship product is called MOTIV, a bioresorbable coronary stent that is designed to fulfill the temporary need for a stent and then fade away, leaving only the healed vessel behind. This product is utilized for the treatment of coronary artery disease. REVA Medical has a broad strategic relationship with Boston Scientific Corporation, a worldwide developer and marketer of interventional medical devices. The company was founded in 1998 and is based in San Diego, California.

Intella Interventional Systems

Stent systems develops angioplasty catheters and guidewires, and related interventional products

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.